ATE244574T1 - Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns - Google Patents

Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Info

Publication number
ATE244574T1
ATE244574T1 AT97917532T AT97917532T ATE244574T1 AT E244574 T1 ATE244574 T1 AT E244574T1 AT 97917532 T AT97917532 T AT 97917532T AT 97917532 T AT97917532 T AT 97917532T AT E244574 T1 ATE244574 T1 AT E244574T1
Authority
AT
Austria
Prior art keywords
morphogens
nervous system
central nervous
morphogen
ischemia
Prior art date
Application number
AT97917532T
Other languages
German (de)
English (en)
Inventor
Marc F Charette
Seth P Finklestein
Original Assignee
Curis Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE244574(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc, Gen Hospital Corp filed Critical Curis Inc
Application granted granted Critical
Publication of ATE244574T1 publication Critical patent/ATE244574T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Protection Of Generators And Motors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97917532T 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns ATE244574T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
PCT/US1997/004177 WO1997034626A1 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Publications (1)

Publication Number Publication Date
ATE244574T1 true ATE244574T1 (de) 2003-07-15

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97917532T ATE244574T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
AT03010945T ATE493141T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03010945T ATE493141T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Country Status (11)

Country Link
US (4) US6214796B1 (OSRAM)
EP (3) EP1364655B1 (OSRAM)
JP (2) JP4847634B2 (OSRAM)
KR (1) KR20000064752A (OSRAM)
CN (1) CN1181885C (OSRAM)
AT (2) ATE244574T1 (OSRAM)
AU (2) AU725341B2 (OSRAM)
CA (2) CA2249368A1 (OSRAM)
DE (2) DE69740089D1 (OSRAM)
ES (1) ES2201287T5 (OSRAM)
WO (2) WO1997034618A1 (OSRAM)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
EP0698094B1 (en) 1993-05-12 2004-02-04 Genetics Institute, LLC Bmp-11 compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
JP3717930B2 (ja) 1993-12-07 2005-11-16 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー Ｂｍｐ−１２、ｂｍｐ−１３およびそれらの腱誘導組成物
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
DK0980252T3 (da) * 1997-05-05 2005-01-31 Curis Inc Terapier til akut nyresvigt
JP2001526788A (ja) * 1997-05-30 2001-12-18 クリエイティブ バイオモレキュールズ，インコーポレイテッド 組織形態形成および活性を評価するための方法
WO1999028341A2 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
JP2003507349A (ja) * 1999-08-18 2003-02-25 ザ ゼネラル ホスピタル コーポレーション 中枢神経系への損傷からの回復を促進する方法、組成物およびキット
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
AU2001268147B2 (en) * 2000-06-01 2006-05-04 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
EP1399023B1 (en) 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
KR20040048379A (ko) * 2001-06-01 2004-06-09 싸이트 테라피스 인코포레이티드 Ｔ 세포 유도된 조직 복구 및 재생
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
EP1623017B1 (en) 2003-05-08 2010-09-15 Life Technologies Corporation Generation and isolation of antigen-specific t cells
CA2897218A1 (en) 2004-06-17 2006-01-26 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
EP1766077B1 (en) * 2004-06-21 2012-03-28 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
EP1782821A4 (en) * 2004-07-29 2009-11-11 Anges Mg Inc MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
SI2497780T1 (sl) 2005-09-20 2015-08-31 Thrasos Innovation, Inc. Spojine, povezane s TDF, in njihovi analogi
US20090233842A1 (en) 2005-11-12 2009-09-17 Prtzker Neuropsychiatric Research Fund Llc Fgf2-related methods for diagnosing and treating depression
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP2121142B1 (en) * 2007-01-25 2013-04-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Use of gdf-5 for the improvement or maintenance of dermal appearance
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
CN101801405A (zh) 2007-08-07 2010-08-11 先进科技及再生医学有限责任公司 包含于酸性水溶液中的gdf-5的蛋白质配方
US7947649B2 (en) * 2008-04-14 2011-05-24 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered GDF-5 formulations
AU2010213591B2 (en) * 2009-02-12 2013-11-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
CN102369016A (zh) * 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
WO2010103070A2 (en) 2009-03-12 2010-09-16 Charité - Universitätsmedizin Berlin Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2011035094A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
AU2011292810B2 (en) 2010-08-20 2015-04-30 Wyeth Llc Designer osteogenic proteins
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
HK1198333A1 (zh) * 2011-07-19 2015-04-02 Thrasos Innovation, Inc. 抗纤维化肽及其在用於治疗以纤维化为特徵的疾病和病症的方法中的用途
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
US20160220640A1 (en) * 2013-06-11 2016-08-04 The Brigham And Women's Hospital, Inc. Methods and compositions for increasing neurogenesis and angiogenesis
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2020010180A1 (en) * 2018-07-03 2020-01-09 Cardio Vascular Bio Therapeutics, Inc. Compositions and methods for treating stroke
US20230095167A1 (en) * 2020-02-20 2023-03-30 Universiteit Maastricht Detection method of circulating bmp10 (bone morphogenetic protein 10)
EP4154001A4 (en) * 2020-05-19 2024-06-05 Elevian, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
WO1990000619A1 (en) 1988-07-08 1990-01-25 University College London Analysis of cell modifying substances
WO1990000900A1 (en) 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
DK0448704T3 (da) 1989-10-17 1999-04-06 Stryker Corp Osteogene anordninger
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
ATE184052T1 (de) 1990-06-15 1999-09-15 Carnegie Inst Of Washington Gdf-1 und uog1 proteine
DE69133338T2 (de) 1990-09-26 2004-04-15 Genetics Institute, LLC, Cambridge Bmp-5-derivate
AU663689B2 (en) 1990-10-18 1995-10-19 Stryker Corporation Osteogenic peptides
AU660635B2 (en) 1990-11-16 1995-07-06 Celtrix Pharmaceuticals, Inc. A beta-type transforming growth factor
WO1992009301A1 (en) 1990-11-27 1992-06-11 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
JP3356775B2 (ja) 1990-11-30 2002-12-16 セルトリックス ファーマシューティカルズ， インコーポレイテッド ＴＧＦ―βとの共同的組合せによる骨修復のための骨形成タンパク質の使用
JP3627985B2 (ja) * 1991-03-11 2005-03-09 キュリス インコーポレイテッド タンパク質により誘導される形態形成
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
CA2102808A1 (en) 1991-05-10 1992-11-11 Hanne Bentz Targeted delivery of bone growth factors
EP0542971A1 (en) 1991-05-10 1993-05-26 The Salk Institute For Biological Studies CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-$g(b) SUPERFAMILY
US5597897A (en) 1991-06-21 1997-01-28 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
CA2108770C (en) 1991-06-25 2007-04-03 John M. Wozney Bmp-9 compositions
ES2149776T5 (es) 1991-08-30 2004-07-01 Curis, Inc. Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
JP3616089B2 (ja) 1991-08-30 2005-02-02 キュリス インコーポレイテッド 形態形成誘導蛋白のスクリーニング方法
ATE308336T1 (de) 1991-08-30 2005-11-15 Curis Inc Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
DE69233022T2 (de) 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
JP4101284B2 (ja) 1991-11-22 2008-06-18 ジェネンテック・インコーポレーテッド 神経損傷を改善するｔｇｆ−ｂｅｔａ
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
AU681594B2 (en) * 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
JPH09501932A (ja) † 1993-08-26 1997-02-25 ジェネティックス・インスティテュート・インコーポレイテッド ヒト・骨形態形成蛋白を用いる神経再生
AU7605394A (en) 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
CA2174098C (en) 1993-10-14 2011-01-25 Douglas A. Melton Method of inducing and maintaining neuronal cells
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
JP2000507939A (ja) 2000-06-27
US20010039261A1 (en) 2001-11-08
AU2552997A (en) 1997-10-10
EP1364655A1 (en) 2003-11-26
US6407060B1 (en) 2002-06-18
DE69723429T2 (de) 2004-04-22
WO1997034626A1 (en) 1997-09-25
CN1219133A (zh) 1999-06-09
DE69723429T3 (de) 2007-09-20
JP4847634B2 (ja) 2011-12-28
ES2201287T3 (es) 2004-03-16
EP0904093A1 (en) 1999-03-31
EP0894004A1 (en) 1999-02-03
ATE493141T1 (de) 2011-01-15
JP2000506894A (ja) 2000-06-06
DE69740089D1 (de) 2011-02-10
CA2249596C (en) 2011-11-08
ES2201287T5 (es) 2007-10-16
EP0904093A4 (en) 2004-11-17
CA2249368A1 (en) 1997-09-25
WO1997034618A1 (en) 1997-09-25
KR20000064752A (ko) 2000-11-06
CN1181885C (zh) 2004-12-29
AU725341B2 (en) 2000-10-12
US20030022830A1 (en) 2003-01-30
EP0894004B1 (en) 2003-07-09
CA2249596A1 (en) 1997-09-25
AU2582397A (en) 1997-10-10
DE69723429D1 (de) 2003-08-14
AU734312B2 (en) 2001-06-07
US6214796B1 (en) 2001-04-10
EP1364655B1 (en) 2010-12-29
EP0894004B2 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
ATE244574T1 (de) Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
DE3587266D1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
EP0464932A3 (en) Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
IL91322A0 (en) Acid-resistant fgf composition and method of treating ulcerating diseases of the gastrointestinal tract
DE69731652D1 (de) Verfahren zur behandlung von endothelialen verletzungen
DE69232287D1 (de) Verfahren und zusammensetzung zur verminderung von reperfusionsschäden des myokards
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
MX9701187A (es) Nuevas lactamas naftofusionadas n-substituidas.
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
EP0577025A3 (de) Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
ATE118350T1 (de) Zusammensetzungen und verfahren zur behandlung von hautkrankheiten und zur aktivierung der wundheilung.
ATE291918T1 (de) Kombinationstherapie zur behandlung von tumoren
ATE238793T1 (de) Verfahren zur förderung von ovulation und geburt bei säugetieren
EP0435177A3 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
Baines et al. Selective activity of a proctolin analogue reveals the existence of two receptor subtypes
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
ZA873928B (en) Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties